Obesity medications have created a new type of client with unique needs. One in eight adults (12%) says they have taken a GLP-1 agonist. Once there is sufficient supply and, assuming moderate levels of insurance coverage and expected eating pattern shifts, an estimated 45 billion calories/week could drop out of the US diet due to GLP-1 use.

That's if only 10-15% of the total prescription-eligible population (>165 million Americans) end up taking the medications. This means these clients are not only spending their money differently but less on groceries while still figuring out how to integrate their new diet into their home and social life.

We need to better understand this population and how to best support them, especially as the medications become more affordable and accessible. We need to recognize the potential unintended consequences medication users' decisions may have including how their dietary habits and behaviors could influence how and what their family eats but, more broadly, drive product innovation and impact the food supply chain.

This panel discussion will include an overview of proprietary research on who these consumers are and offer a range of perspectives on how to meet their needs while presenting opportunities for collaboration.